Free shipping on all orders over $ 500

Pazopanib HCl (GW786034)

Cat. No. M5863

All AbMole products are for research use only, cannot be used for human consumption.

Pazopanib HCl (GW786034) Structure
Synonym:

GW786034; Pazopanib Hydrochloride

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 36 In stock
1mg USD 20 In stock
5mg USD 30 In stock
10mg USD 48 In stock
50mg USD 109 In stock
100mg USD 150 In stock
200mg USD 254 In stock
500mg USD 388 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. In cellular assays, in addition to inhibiting the VEGF-induced proliferation of HUVECs, Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR-2 in HUVEC cells with an IC50 of ~8 nM. Pazopanib possesses good pharmacokinetics in rat, dog, and monkey with low clearances (1.4-1.7 mL/min/kg) and good oral bioavailabilities (72, 47, 65%) dosed at 10, 1, and 5 mg/kg, respectively.

Product Citations
Chemical Information
Molecular Weight 473.98
Formula C21H23N7O2S.HCl
CAS Number 635702-64-6
Solubility (25°C) DMSO 10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Motzer RJ, et al. N Engl J Med. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Related VEGFR/PDGFR Products
Ramucirumab

Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D).

ABT-869

ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR.

Tivozanib (AV-951)

Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively.

Axitinib

Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit.

Regorafenib

Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pazopanib HCl (GW786034), GW786034; Pazopanib Hydrochloride supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.